Amphastar PharmaceuticalsAMPH +3.52%83 PEG Ratio is 0.23 as of Jun. 27, 2026, which is at its 10-year median of 0.23. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.79 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 347 Drug Manufacturers companies, Amphastar Pharmaceuticals ranks better than 97.41% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Amphastar Pharmaceuticals's PEG Ratio or its related term are showing as below:
AMPH'
s PEG Ratio Range Over the Past 10 Years
Min: 0.1 Med: 0.23 Max: 2.27
Current: 0.23
During the past 13 years, Amphastar Pharmaceuticals's highest PEG Ratio was 2.27. The lowest was 0.10. And the median was 0.23.
AMPH's PEG Ratio is ranked better than 97.41% of 347
companies
in the Drug Manufacturers industry
Industry Median: 1.71
vs AMPH: 0.23
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Amphastar Pharmaceuticals (NAS:AMPH) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Amphastar Pharmaceuticals PEG Ratio Related Terms
Amphastar Pharmaceuticals PEG Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Amphastar Pharmaceuticals (AMPH) has a PEG Ratio of 0.23 as of Jun. 27, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Amphastar Pharmaceuticals and its competitors. This is near median its historical median of 0.23. Over the past decade, Amphastar Pharmaceuticals' PEG Ratio has ranged from 0.10 to 2.27. According to the industry distribution chart, Amphastar Pharmaceuticals ranks #9 out of 347 companies in the Drug Manufacturers industry, placing it in the top 2.6%.
Is Amphastar Pharmaceuticals' PEG Ratio too high?
Amphastar Pharmaceuticals' current PEG Ratio of 0.23 is near median its 10-year median of 0.23. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 2.27. The Drug Manufacturers industry median PEG Ratio is 1.71. Amphastar Pharmaceuticals' value of 0.23 is 86.5% below this industry median. Based on the distribution chart, Amphastar Pharmaceuticals ranks #9 out of 347 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' PEG Ratio compare to ETON and ESPR?
According to the Drug Manufacturers industry distribution chart, Amphastar Pharmaceuticals ranks #9 out of 347 companies for PEG Ratio. This places Amphastar Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.71. Amphastar Pharmaceuticals' value of 0.23 is 86.5% below this benchmark. Historically, Amphastar Pharmaceuticals' own PEG Ratio has ranged from 0.10 to 2.27 over the past decade. While the company's 10-year median is 0.23 vs. the industry median of 1.71, Amphastar Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.71, based on 347 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current PEG Ratio of 0.23 is 86.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Amphastar Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current PEG Ratio is 0.23, which is near median its own 10-year median of 0.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.79, compared to a current price of $21.78 — trading 55.4% below its estimated fair value. The current PEG Ratio is 0.23, which is near median its 10-year median of 0.23 and 86.5% below the Drug Manufacturers industry median of 1.71. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current PEG Ratio is 0.23 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued.
The current stock price of $21.78 is trading 55.4% below its estimated GF Value™ of $48.79.
GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for AMPH:
PEG Ratio: 0.23 (near median its 10-year median of 0.23)
GF Value™: $48.79 vs. price of $21.78 (55.4% below fair value)
Industry Position: 86.5% below the Drug Manufacturers median (#9 of 347)
No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score
Get the complete analysis for AMPH
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMPH has been successfully added to your 
